Skip to main content
. 2020 Apr;26(4):10.18553/jmcp.2020.19329. doi: 10.18553/jmcp.2020.19329
Market Share Enzalutamide + ADT, % Apalutamide + ADT, % Bicalutamide + ADT, % ADT, %
Without enzalutamide
  Year 1 0.0 5.7 28.5 65.8
  Year 2 0.0 16.0 25.4 58.6
  Year 3 0.0 27.0 22.1 50.9
With enzalutamide
  Year 1 5.7 5.4 26.9 62.0
  Year 2 15.9 13.5 21.4 49.3
  Year 3 25.8 20.0 16.4 37.8

ADT = androgen deprivation therapy.